Terminated
PHASE2, PHASE3
INTERVENTIONAL
NCT05011513
Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR).
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The primary hypothesis to be tested is whether or not there is a difference in time to sustained alleviation of all targeted COVID-19 signs and symptoms through Day 28 between PF-07321332/ritonavir and placebo.
Detailed Description
Throughout the study period, provision will be made to allow study visits to be conducted at a participant's home or at another non-clinic location, if available. The total study duration is up to 24 weeks.
Interventions
Name:
PF-07321332
Type:
DRUG
Description:
PF-07321332 (tablet)
Name:
Ritonavir
Type:
DRUG
Description:
Ritonavir (capsule)
Name:
Placebo
Type:
DRUG
Description:
Placebo (tablet)
Name:
Placebo
Type:
DRUG
Description:
Placebo (capsule)
Primary Outcomes
Measure:
Time to Sustained Alleviation of Overall COVID-19 Signs and Symptoms Through Day 28
TimeFrame:
From Day 1 to Day 28
Description:
Sustained alleviation of targeted COVID-19 signs/symptoms was defined as the event occurring on the first 4 consecutive days when all symptoms scored as moderate or severe at the time of enrollment were scored as mild or absent and those scored mild or absent at the time of enrollment were scored as absent. Missing severity at baseline was considered as mild. Time to sustained alleviation of all targeted COVID-19 signs and symptoms through Day 28, was calculated as time (days) from start of study intervention or placebo (Day 1) until sustained alleviation of all targeted COVID-19 associated signs and symptoms. In this outcome measure time to sustained alleviation is reported consolidated for overall COVID-19 signs and symptoms.
Trial Information
NCT ID
NCT05011513
Status
Terminated
Study Type
INTERVENTIONAL
Phases
PHASE2, PHASE3
Sponsor
Pfizer
Last Updated
December 15, 2025